High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer

• Published in: American journal of clinical oncology Vol. 24; no. 2; p. 138
• Main Authors: Milla-Santos, A, Milla, L, Rallo, L, Solano, V
• Format: Journal Article
• Language: English
• Published: United States 01.04.2001
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Docetaxel; Drug Administration Schedule; Epirubicin - administration & dosage; Granulocyte Colony-Stimulating Factor - therapeutic use; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Paclitaxel - administration & dosage; Paclitaxel - analogs & derivatives; Recombinant Proteins - therapeutic use; Survival Analysis; Taxoids

On the basis of preclinical and clinical data, we designed a phase II study to determine the efficacy and feasibility of high-dose epirubicin plus docetaxel (Taxotere) with lenograstim support, as first-line therapy for patients with advanced breast cancer. Patients with histologic evidence of metas...